Lv4
554 积分 2025-01-08 加入
Post-translational modifications talk and crosstalk to class IIa histone deacetylases
13小时前
待确认
Chemoproteomics-guided development of SLC15A4 inhibitors with anti-inflammatory activity
4个月前
已完结
Solute carrier family 15 member 4, an emerging therapeutic target for systemic lupus erythematosus
4个月前
已完结
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer
5个月前
已完结
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer
5个月前
已完结
Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer
5个月前
已完结
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial
6个月前
已完结
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial
6个月前
已完结
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial
7个月前
已完结
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial
7个月前
已完结